GlassScriptPhysician profile
Fredrick V Osorio
NPI 1306830229
$4,027.10
in general payments reported to CMS, 2019-2025
27 companies · $843 in 2025
The $843 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $160 · 2021: $528 · 2022: $577 · 2023: $685 · 2024: $649 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.31 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $652.50 | 2019-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $396.26 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $386.42 | 2019-2024 | Farxiga |
| Travere Therapeutics, INC. | $364.06 | 2022-2025 | |
| Akebia Therapeutics INC | $293.74 | 2019-2025 | Vafseo, Auryxia |
| Horizon Therapeutics Plc | $228.43 | 2020-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $201.94 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $190.56 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $169.65 | 2019-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $145.06 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $144.19 | 2021-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $126.47 | 2021-2025 | Terlivaz |
| Nxstage Medical, INC. | $124.02 | 2023 | Nxstage System One |
| Baxter Healthcare | $123.64 | 2024 | |
| Vantive US Healthcare LLC | $104.90 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $101.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $47.86 | 2024-2025 | |
| Ardelyx, INC. | $45.94 | 2023-2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $29.45 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.25 | 2019-2021 | |
| Daiichi Sankyo INC. | $26.71 | 2023 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $17.05 | 2023 | |
| Apellis Pharmaceuticals, INC. | $17.03 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.88 | 2025 | Jardiance |
| Genentech USA, INC. | $14.87 | 2019 | |
| Genzyme Corporation | $14.38 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.14 | 2023 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick Osorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.